DVA · DaVita Inc. · Stock research

Current Thesis

The re-rate leg tracked in this coverage since May ended at the Q2 print. On 2026-08-04 DaVita beat on both lines — adjusted EPS $4.02 against $3.88 consensus, revenue $3.554B against $3.496B — and then affirmed rather than raised FY26 adjusted EPS of $14.10–$15.20, a $14.65 midpoint sitting under the $14.82 consensus the market carried into the print. On the call management guided full-year revenue-per-treatment growth of 1–2%, which it said implies slightly negative year-over-year RPT in the second half on declining commercial mix and lower binder revenue. Price settled the argument: the 2026-08-07 close of $183.77 is 23.7% below the 52-week high of $240.96, with RSI(14) at 19.7. The $203 weekly-close level flagged in the prior note as the June breakout shelf is gone. What is left is a cheap, low-beta operator with an intact volume story, a questioned margin story, and a sell-side that is now marking targets down toward price instead of up away from it.

Bullish and bearish views on DaVita Inc.

The model's bull view on DaVita Inc. (DVA), in brief: Volume — the GLP-1 inversion — printed. Q2 US dialysis treatments 7,226,600, 92,649 per normalized day, +1.09% vs Q1's 91,650 and +56bps year over year (2026-08-04 release and call). Management moved FY treatment growth to the top end of the 25–50bps range and attributed it to… The bear view: The guide is the break. FY26 adjusted EPS affirmed at $14.10–$15.20 (midpoint $14.65) versus $14.82 consensus, with FY adjusted operating income $2,150–$2,250M. A defensive compounder that re-rates on estimate revisions cannot keep re-rating while the guide midpoint sits under… Both cases follow in full.

Bull Case

• Volume — the GLP-1 inversion — printed. Q2 US dialysis treatments 7,226,600, 92,649 per normalized day, +1.09% vs Q1's 91,650 and +56bps year over year (2026-08-04 release and call). Management moved FY treatment growth to the top end of the 25–50bps range and attributed it to improved patient mortality.
• Both lines beat on 2026-08-04: adjusted EPS $4.02 vs $3.88 estimate; revenue $3.554B vs $3.496B estimate.
• Cash and the standing bid. Q2 free cash flow $256M against an FY guide of $1,000–1,250M; 2.2M shares repurchased for $348M in Q2, $751M year to date (2026-08-04 release). The formulaic repurchase that keeps Berkshire's stake at or below 45% shrinks the count independent of tape.
• Targets now sit above spot. TD Cowen upgraded to Buy on 2026-08-07 while cutting its target to $220; Truist stayed at Hold with $215 the same day; Barclays lifted to $224 on 2026-08-05. Against a $183.77 close that cluster is 17–22% higher — the inverse of the June condition, when spot had run through every published target.
• Balance sheet is not the constraint. Net leverage 3.37x; census ~298,500 patients across 3,266 outpatient centers (2026-08-04).

Bear Case

• The guide is the break. FY26 adjusted EPS affirmed at $14.10–$15.20 (midpoint $14.65) versus $14.82 consensus, with FY adjusted operating income $2,150–$2,250M. A defensive compounder that re-rates on estimate revisions cannot keep re-rating while the guide midpoint sits under the estimate.
• Revenue per treatment fell sequentially: $415.87 in Q2 versus $417.59 in Q1, a $1.72 decline, with management flagging slightly negative year-over-year RPT in H2 on commercial-mix erosion and lower binder revenue (2026-08-04 call). Q2 adjusted operating income was $579M.
• Berkshire keeps selling. The Form 4 disclosed 2026-08-04 shows 182,980 shares at an average $199.55, leaving roughly 28.7M shares, following an earlier sale of 1,220,376 shares at an average $149.84. Whether or not it is mechanical under the standstill, the largest holder has been a supplier of stock through the whole 2026 advance.
• Structure is broken. −23.7% from the high, RSI(14) 19.7, the $203 shelf lost, and two of the three post-print analyst actions were target cuts (2026-08-07).
• No peer bid. Managed-care comparables (UNH, HUM, CVS, ELV) have been weak through 2026; the 2026 advance was idiosyncratic, so nothing thematic sits under a bounce.
• Standing tail risks: CMS ESRD rate-setting, recurring DaVita-versus-insurer litigation, and net leverage at 3.37x.

Setup & Price Structure

• Basis: 2026-08-07 close $183.77; 52-week high $240.96; −23.7% from the high; three-month return −7.5%; RSI(14) 19.7.
• Life-cycle: DEAD for the leg this coverage described. What was being bought between May and July — census recovery plus the GLP-1 mortality inversion driving a sell-side chase to fresh highs — failed on 2026-08-04, and the structure that carried it broke in the sessions after. The three-month return of −7.5% means the post-Q1-print advance has been fully surrendered.
• Crowding and positioning, as observables: RSI(14) at 19.7 is a sub-20 reading; price is under its declining averages, inverting the extension condition that defined the June read. The largest holder sold into strength again at an average $199.55 (Form 4, 2026-08-04). Two target cuts landed on 2026-08-07 against one raise on 2026-08-05. No earnings date falls inside the next 30 days.
• What a new leg would require: a base. Sub-20 RSI with no confirmed shelf beneath the 2026 range describes a falling structure. Underwriting the name at $183.77 is underwriting mean reversion to the $215–$224 target cluster, a different proposition from the momentum leg that ended on 2026-08-04.

Catalyst Calendar (next 30 days)

• 2026-08-08 → 2026-09-07 — no confirmed company event. As of 2026-08-08 DaVita has not announced a Q3 2026 conference-call date.
• 2026-08-14 — Q2 2026 13F deadline, including Berkshire Hathaway's. Limited read-through: as a >10% holder Berkshire discloses DVA sales on Form 4 in near real time (most recent 2026-08-04), so the 13F adds little beyond what Form 4 already showed.
• Ongoing — further Berkshire Form 4 filings. Each prints an average execution price and a remaining share count.
• ~2026-10-28 (est.) — Q3 2026 print. Unconfirmed; DaVita has reported Q3 in late October in recent years. First datapoint that can move FY guidance off $14.10–$15.20.
• ~2026-10-31 (est.) — CMS ESRD PPS CY2027 final rule, historically issued at the end of October or start of November.

What Would Change Our Mind

• Revenue per treatment is the datapoint that flips this. FY guidance of 1–2% RPT growth embeds slightly negative year-over-year RPT in H2. A Q3 print (~2026-10-28, est.) that holds RPT at or above the Q2 $415.87 and lifts the FY EPS midpoint above the $14.82 consensus would restart the estimate-revision engine the 2026 advance ran on.
• Structural repair would be visible: reclaiming and holding above $203, the shelf the June breakout was built on, is the first evidence the damage is reparable. Failure to trade back above it before the Q3 print keeps the label at DEAD.
• The downside condition, stated gradeably: a weekly close below $175 puts the name decisively under the entire post-Q1-print range and argues the drawdown is a de-rating on the H2 margin guide rather than a print-reaction overshoot.
• Target migration matters. The $215–$224 cluster (Truist $215 and TD Cowen $220 on 2026-08-07, Barclays $224 on 2026-08-05) is the only remaining bid narrative. Targets cut below $200 would remove it.

Correlation Notes

• Beta ~0.84–0.91. Index direction explains little of the variance; prints and estimate revisions do the work.
• No managed-care cluster. UNH, HUM, CVS and ELV have been weak through 2026, so peer action neither explains this drawdown nor supports a recovery.
• The one genuine read-across is Fresenius Medical Care, the other scaled dialysis operator. A DaVita-specific commercial-mix problem should not appear there; a US reimbursement problem should.
• GLP-1 complex runs the other way now. The late-2025 finding that GLP-1 use cut dialysis-patient mortality ~17% inverted the old demand-destruction bear case, and DaVita's own FY volume upgrade on 2026-08-04 was attributed to mortality improvement — GLP-1 adoption headlines read as volume-positive for this name.
• Float mechanics are unusual. The standstill-linked buyback ($348M in Q2, $751M YTD) is a persistent bid while Berkshire's Form 4 sales are a persistent supply; both operate regardless of sentiment.